Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience

Yoshihide Ueda, Toru Ikegami, Akihiko Soyama, Nobuhisa Akamatsu, Masahiro Shinoda, Kohei Ishiyama, Masaki Honda, Shigeru Marubashi, Hideaki Okajima, Tomoharu Yoshizumi, Susumu Eguchi, Norihiro Kokudo, Yuko Kitagawa, Hideki Ohdan, Yukihiro Inomata, Hiroaki Nagano, Ken Shirabe, Shinji Uemoto, Yoshihiko Maehara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: This study aimed to clarify the efficacy and safety of simeprevir, a second-generation NS3/4A inhibitor, with peginterferon and ribavirin for recurrent hepatitis C after liver transplantation. Methods: A retrospective cohort study of living-donor liver transplant recipients with recurrent hepatitis C with the hepatitis C virus genotype 1 treated with either simeprevir- or telaprevir-based triple therapy was carried out at eight Japanese liver transplant centers. Results: Simeprevir- and telaprevir-based triple therapies were given to 79 and 36 patients, respectively. Of the 79 patients treated with simeprevir-based triple therapy, 44 (56%) achieved sustained virological response 12 weeks (SVR12) after treatment ended, and there was no significant difference in the SVR12 between the simeprevir- and telaprevir-based triple therapy groups (69%). The rates of adverse events were not significantly different between the simeprevir- and telaprevir-based triple therapy groups, although the rate of patients who received blood cell transfusion and erythropoietin due to anemia and had renal insufficiency were significantly higher in the telaprevir group than in the simeprevir group. Three baseline factors, the presence of prior dual therapy with peginterferon and ribavirin (P = 0.001), a non-responder to the prior dual therapy (P < 0.001), and male sex (P = 0.040), were identified as significant predictive factors for non-SVR with simeprevir-based triple therapy. Conclusion: Simeprevir-based triple therapy for recurrent hepatitis C after living-donor liver transplantation resulted in a high SVR rate and good tolerability, especially in treatment-naïve patients.

Original languageEnglish
Pages (from-to)1285-1293
Number of pages9
JournalHepatology Research
Volume46
Issue number13
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Ribavirin
Living Donors
Hepatitis C
Liver Transplantation
Therapeutics
Group Psychotherapy
telaprevir
Simeprevir
Liver
Erythropoietin
Blood Transfusion
Hepacivirus
Renal Insufficiency
Anemia
Blood Cells
Cohort Studies
Retrospective Studies
Genotype
Transplants
Safety

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation : A Japanese multicenter experience. / Ueda, Yoshihide; Ikegami, Toru; Soyama, Akihiko; Akamatsu, Nobuhisa; Shinoda, Masahiro; Ishiyama, Kohei; Honda, Masaki; Marubashi, Shigeru; Okajima, Hideaki; Yoshizumi, Tomoharu; Eguchi, Susumu; Kokudo, Norihiro; Kitagawa, Yuko; Ohdan, Hideki; Inomata, Yukihiro; Nagano, Hiroaki; Shirabe, Ken; Uemoto, Shinji; Maehara, Yoshihiko.

In: Hepatology Research, Vol. 46, No. 13, 01.12.2016, p. 1285-1293.

Research output: Contribution to journalArticle

Ueda, Y, Ikegami, T, Soyama, A, Akamatsu, N, Shinoda, M, Ishiyama, K, Honda, M, Marubashi, S, Okajima, H, Yoshizumi, T, Eguchi, S, Kokudo, N, Kitagawa, Y, Ohdan, H, Inomata, Y, Nagano, H, Shirabe, K, Uemoto, S & Maehara, Y 2016, 'Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience', Hepatology Research, vol. 46, no. 13, pp. 1285-1293. https://doi.org/10.1111/hepr.12684
Ueda, Yoshihide ; Ikegami, Toru ; Soyama, Akihiko ; Akamatsu, Nobuhisa ; Shinoda, Masahiro ; Ishiyama, Kohei ; Honda, Masaki ; Marubashi, Shigeru ; Okajima, Hideaki ; Yoshizumi, Tomoharu ; Eguchi, Susumu ; Kokudo, Norihiro ; Kitagawa, Yuko ; Ohdan, Hideki ; Inomata, Yukihiro ; Nagano, Hiroaki ; Shirabe, Ken ; Uemoto, Shinji ; Maehara, Yoshihiko. / Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation : A Japanese multicenter experience. In: Hepatology Research. 2016 ; Vol. 46, No. 13. pp. 1285-1293.
@article{79b0851c39f74533b57c41d12b788e33,
title = "Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience",
abstract = "Aim: This study aimed to clarify the efficacy and safety of simeprevir, a second-generation NS3/4A inhibitor, with peginterferon and ribavirin for recurrent hepatitis C after liver transplantation. Methods: A retrospective cohort study of living-donor liver transplant recipients with recurrent hepatitis C with the hepatitis C virus genotype 1 treated with either simeprevir- or telaprevir-based triple therapy was carried out at eight Japanese liver transplant centers. Results: Simeprevir- and telaprevir-based triple therapies were given to 79 and 36 patients, respectively. Of the 79 patients treated with simeprevir-based triple therapy, 44 (56{\%}) achieved sustained virological response 12 weeks (SVR12) after treatment ended, and there was no significant difference in the SVR12 between the simeprevir- and telaprevir-based triple therapy groups (69{\%}). The rates of adverse events were not significantly different between the simeprevir- and telaprevir-based triple therapy groups, although the rate of patients who received blood cell transfusion and erythropoietin due to anemia and had renal insufficiency were significantly higher in the telaprevir group than in the simeprevir group. Three baseline factors, the presence of prior dual therapy with peginterferon and ribavirin (P = 0.001), a non-responder to the prior dual therapy (P < 0.001), and male sex (P = 0.040), were identified as significant predictive factors for non-SVR with simeprevir-based triple therapy. Conclusion: Simeprevir-based triple therapy for recurrent hepatitis C after living-donor liver transplantation resulted in a high SVR rate and good tolerability, especially in treatment-na{\"i}ve patients.",
author = "Yoshihide Ueda and Toru Ikegami and Akihiko Soyama and Nobuhisa Akamatsu and Masahiro Shinoda and Kohei Ishiyama and Masaki Honda and Shigeru Marubashi and Hideaki Okajima and Tomoharu Yoshizumi and Susumu Eguchi and Norihiro Kokudo and Yuko Kitagawa and Hideki Ohdan and Yukihiro Inomata and Hiroaki Nagano and Ken Shirabe and Shinji Uemoto and Yoshihiko Maehara",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/hepr.12684",
language = "English",
volume = "46",
pages = "1285--1293",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "13",

}

TY - JOUR

T1 - Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation

T2 - A Japanese multicenter experience

AU - Ueda, Yoshihide

AU - Ikegami, Toru

AU - Soyama, Akihiko

AU - Akamatsu, Nobuhisa

AU - Shinoda, Masahiro

AU - Ishiyama, Kohei

AU - Honda, Masaki

AU - Marubashi, Shigeru

AU - Okajima, Hideaki

AU - Yoshizumi, Tomoharu

AU - Eguchi, Susumu

AU - Kokudo, Norihiro

AU - Kitagawa, Yuko

AU - Ohdan, Hideki

AU - Inomata, Yukihiro

AU - Nagano, Hiroaki

AU - Shirabe, Ken

AU - Uemoto, Shinji

AU - Maehara, Yoshihiko

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Aim: This study aimed to clarify the efficacy and safety of simeprevir, a second-generation NS3/4A inhibitor, with peginterferon and ribavirin for recurrent hepatitis C after liver transplantation. Methods: A retrospective cohort study of living-donor liver transplant recipients with recurrent hepatitis C with the hepatitis C virus genotype 1 treated with either simeprevir- or telaprevir-based triple therapy was carried out at eight Japanese liver transplant centers. Results: Simeprevir- and telaprevir-based triple therapies were given to 79 and 36 patients, respectively. Of the 79 patients treated with simeprevir-based triple therapy, 44 (56%) achieved sustained virological response 12 weeks (SVR12) after treatment ended, and there was no significant difference in the SVR12 between the simeprevir- and telaprevir-based triple therapy groups (69%). The rates of adverse events were not significantly different between the simeprevir- and telaprevir-based triple therapy groups, although the rate of patients who received blood cell transfusion and erythropoietin due to anemia and had renal insufficiency were significantly higher in the telaprevir group than in the simeprevir group. Three baseline factors, the presence of prior dual therapy with peginterferon and ribavirin (P = 0.001), a non-responder to the prior dual therapy (P < 0.001), and male sex (P = 0.040), were identified as significant predictive factors for non-SVR with simeprevir-based triple therapy. Conclusion: Simeprevir-based triple therapy for recurrent hepatitis C after living-donor liver transplantation resulted in a high SVR rate and good tolerability, especially in treatment-naïve patients.

AB - Aim: This study aimed to clarify the efficacy and safety of simeprevir, a second-generation NS3/4A inhibitor, with peginterferon and ribavirin for recurrent hepatitis C after liver transplantation. Methods: A retrospective cohort study of living-donor liver transplant recipients with recurrent hepatitis C with the hepatitis C virus genotype 1 treated with either simeprevir- or telaprevir-based triple therapy was carried out at eight Japanese liver transplant centers. Results: Simeprevir- and telaprevir-based triple therapies were given to 79 and 36 patients, respectively. Of the 79 patients treated with simeprevir-based triple therapy, 44 (56%) achieved sustained virological response 12 weeks (SVR12) after treatment ended, and there was no significant difference in the SVR12 between the simeprevir- and telaprevir-based triple therapy groups (69%). The rates of adverse events were not significantly different between the simeprevir- and telaprevir-based triple therapy groups, although the rate of patients who received blood cell transfusion and erythropoietin due to anemia and had renal insufficiency were significantly higher in the telaprevir group than in the simeprevir group. Three baseline factors, the presence of prior dual therapy with peginterferon and ribavirin (P = 0.001), a non-responder to the prior dual therapy (P < 0.001), and male sex (P = 0.040), were identified as significant predictive factors for non-SVR with simeprevir-based triple therapy. Conclusion: Simeprevir-based triple therapy for recurrent hepatitis C after living-donor liver transplantation resulted in a high SVR rate and good tolerability, especially in treatment-naïve patients.

UR - http://www.scopus.com/inward/record.url?scp=84961730243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961730243&partnerID=8YFLogxK

U2 - 10.1111/hepr.12684

DO - 10.1111/hepr.12684

M3 - Article

AN - SCOPUS:84961730243

VL - 46

SP - 1285

EP - 1293

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 13

ER -